Dario Trapani, Medical Oncologist at European Institute of Oncology (IEO), Researcher at Department of Oncology and Hemato-Oncology at University of Milan, shared a post on LinkedIn:
“The trade magazine The Lancet Oncology together with the editors of the The Lancet family have recently launched an appeal to enhance transparency in the way they design but above all report the results of clinical trials in oncology.
By implementing the cornerstones of CONSORT quality reporting and incorporating cancer-specific elements from the Common Sense Oncology ‘s recommendations, the editors call on the community to be more restrained and balanced in the way cancer research is designed, produced, and reported.
‘Many academics are now questioning whether the equilibrium between these two objectives has swung too far: is the focus leaning too much in favour of commercial interests over scientific advance and patient benefit?’ ”
The Italian perspective.
Title: Greater transparency for oncology clinical trials reporting
Authors: David Collingridge, Allison Landman, Robert Brierley, Claudia Schaefer, Jie Cai, Emma Grainger, Sonia Muliyil, Lan-Lan Smith
Read the Full Article.
More posts featuring Dario Trapani.